Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPYK04 in Locally Advanced or Metastatic Solid Tumors
NCT04511845Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of spyk04 in solid tumor, non-small cell lung cancer (NSCLC) and ovarian cancer (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 35 days, Adverse Events at 42 months and 3 more. Started Sep 2020; status: completed.
02
Drugs
spyk04
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT04511845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511845.